Entangled In Pinjol, Indofarma Subsidiary Loses IDR 1.26 Billion

JAKARTA - A subsidiary of PT Indofarma Tbk, PT Indofarma Global Medika (IGM) is estimated to have lost around Rp1.26 billion due to being caught in an online loan or loan.

The President Director of Bio Farma, Shadiq Akasya, always the leader of the Pharmaceutical BUMN Holding, said that the online loan was not carried out in the interest of the company, thus causing IGM to suffer losses.

"Pinjaman melalui fintech bukan untuk kepentingan perusahaan berindikasi merugikan IGM senilai Rp1,26 Miliar," kata Shadiq dalam rapat dengan Komisi VI DPR, di Gedung DPR, Jakarta, Rabu, 19 Juni.

Shadiq said the Supreme Audit Agency (BPK) had examined 18 findings. From these findings, there were 10 of them indicated by fraud.

Selain pinjol, Shadiq mengatakan fraud lainnya yang ditemukan yakni indikasi kerugian atas transaksi unit bisnis Fast Moving Consumer Goods (FMCG) sebesar Rp157,33 miliar.

"Then, the indication of a loss in the emergency room for the loss of deposits is approximately Rp. 35.07 billion, an indication of IGM losses due to deposit losses of Rp. 38 billion," he said.

Then, continued Shadiq, there were indications of IGM losses due to the provision of deposits and interest worth IDR 38.06 billion at Bank Oke.

Furthermore, said Shadiq, indications of IGM losses worth Rp. 18 billion were found for the return of down payment from MMU which did not go to the emergency room account.

"Then, the expenditure of funds and the charge of costs without being based on transactions indicated IGM losses of IDR 24.35 billion," he explained.

Furthermore, he said, the cooperation between the Alkes TeleCTG Distribution and PT ZTI without Memadai's plan indicated a loss to IGM of IDR 4.50 billion for payments that exceeded the value of the invoice and could potentially harm IGM worth IDR 10.43 billion for TeleCTG's unsold stock.

"Then there are also mask business activities without adequate planning indicated fraud, indicated a loss of Rp. 2.67 billion for the decrease in mask inventory value and the potential loss of Rp. 60.24 billion for PT Promedik's bad debt and Rp. 13.11 billion for the remaining supply of masks," he said.

Then, the purchase and sale of the Panbio Rapid Test of PT IGM without adequate planning indicated fraud and the potential loss of Rp56.70 billion for PT Promedik's bad debt.

"Then, PT Indofarma carried out the purchase and sale of PCR Kit COVID-19 in 2020/2021 without adequate planning with indications of fraud and a potential loss of Rp. 5.98 billion for PT Promedik traffic jams and Rp. 9.17 billion for the unsold PCR Kit COVID-19," said Shadiq.